Open AccessCost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
Author(s) -
Mondher Mtibaa,
S. Gupta,
Madhusubramanian Muthukumar,
Jessica Marvel,
Harneet Kaur,
Rie Ishikawa,
Ron Olivenstein
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s336915
Subject(s) - medicine , indacaterol , mometasone furoate , fluticasone propionate , asthma , salmeterol , exacerbation , inhaler , cost effectiveness , dry powder inhaler , corticosteroid , bronchodilator , risk analysis (engineering)
We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 µg, twice daily)+tiotropium (TIO; 5 µg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 µg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma.